- Home
- RITR vs DMAC Comparison
RITR vs DMAC Comparison
Compare RITR & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- DMAC
- Stock Information
- Founded
- RITR 2015
- DMAC 2000
- Country
- RITR Hong Kong
- DMAC United States
- Employees
- RITR N/A
- DMAC N/A
- Industry
- RITR
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- RITR
- DMAC Health Care
- Exchange
- RITR NYSE
- DMAC Nasdaq
- Market Cap
- RITR 283.5M
- DMAC 260.0M
- IPO Year
- RITR 2024
- DMAC N/A
- Fundamental
- Price
- RITR $4.10
- DMAC $4.12
- Analyst Decision
- RITR
- DMAC Strong Buy
- Analyst Count
- RITR 0
- DMAC 4
- Target Price
- RITR N/A
- DMAC $10.75
- AVG Volume (30 Days)
- RITR 391.3K
- DMAC 400.1K
- Earning Date
- RITR 02-15-2025
- DMAC 08-15-2025
- Dividend Yield
- RITR N/A
- DMAC N/A
- EPS Growth
- RITR N/A
- DMAC N/A
- EPS
- RITR 0.09
- DMAC N/A
- Revenue
- RITR $47,948,887.00
- DMAC N/A
- Revenue This Year
- RITR N/A
- DMAC N/A
- Revenue Next Year
- RITR N/A
- DMAC N/A
- P/E Ratio
- RITR $49.35
- DMAC N/A
- Revenue Growth
- RITR 278.44
- DMAC N/A
- 52 Week Low
- RITR $2.24
- DMAC $3.19
- 52 Week High
- RITR $8.75
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- DMAC 47.01
- Support Level
- RITR N/A
- DMAC $4.81
- Resistance Level
- RITR N/A
- DMAC $5.60
- Average True Range (ATR)
- RITR 0.00
- DMAC 0.48
- MACD
- RITR 0.00
- DMAC -0.03
- Stochastic Oscillator
- RITR 0.00
- DMAC 24.10
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.